MARKET NEWS

Gerresheimer & Merck KGaA Transform Primary Packaging Into Digital Twins
Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells & Hair Follicles
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 & BDTX-4933
George Clinical Recruits More than 5,000 Patients in the Global Kidney Patient Trials Network

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Backed by over 90 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.

  EXCLUSIVE ONLINE CONTENT

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership With Emergent BioSolutions

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership With Emergent BioSolutions

SAB Biotherapeutics recently announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Emergent will provide….

VacV Biotherapeutics Emerges From Stealth Mode to Bring Ground-Breaking Cancer Immunotherapies to the Clinic

VacV Biotherapeutics Emerges From Stealth Mode to Bring Ground-Breaking Cancer Immunotherapies to the Clinic

VacV Biotherapeutics recently emerged from stealth mode to advance its promising pipeline of preclinical assets with best-in-class potential, toward the clinic…..

Panoramic Health Launches Clinical Research Division to Drive Discovery of Novel Kidney Disease Therapies

Panoramic Health Launches Clinical Research Division to Drive Discovery of Novel Kidney Disease Therapies

Panoramic Health recently announced the launch of its clinical research division dedicated to advancing kidney care innovation and improving patient outcomes….

Symeres Acquires Exemplify BioPharma, Further Strengthening its Strategic Foothold in the US

Symeres Acquires Exemplify BioPharma, Further Strengthening its Strategic Foothold in the US

Symeres recently announced the acquisition of Exemplify BioPharma, a US based CRO that provides integrated drug development services in Process & Analytical Chemistry and….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

Bespak by Recipharm Webinar: Learn How To Overcome Viscous Formulation Challenges For Parenteral Delivery

Bespak by Recipharm Webinar: Learn How To Overcome Viscous Formulation Challenges For Parenteral Delivery

There have been many challenges holding back widespread adoption of self-administered injectable formulations. One of the most pressing is the need to develop an auto-injector with a fine enough needle for….

  WHITEPAPERS & WEBINARS

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Manufacturing Phase 1 clinical material in as little as 12–16 months

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 9 – Injection Devices
November 16 – Analytical Instrumentation